Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis
| Autor: | Bulent Gurler, Mehmet Gurkan Tatar, Ramazan Yayuspayi, Erol Coskun, Ibrahim Erbagci, Seydi Okumus, Aysegul Comez, Erdal Kaydu |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Adult
Male medicine.medical_specialty Intraocular pressure Visual acuity Turkey genetic structures Corneal subepithelial infiltrate Keratoconjunctivitis Eye Infections Viral Foreign body sensation Adenovirus Infections Human lcsh:Ophthalmology Topical 0.05% cyclosporine A Subepithelial Infiltrate Ophthalmology Medicine Humans In patient Epidemics Retrospective Studies Dose-Response Relationship Drug business.industry Epithelium Corneal Epidemic keratoconjunctivitis Retrospective cohort study General Medicine medicine.disease Prognosis Treatment period eye diseases Surgery lcsh:RE1-994 Cyclosporine Female sense organs medicine.symptom Ophthalmic Solutions business Immunosuppressive Agents Research Article |
| Zdroj: | BMC Ophthalmology BMC Ophthalmology, Vol 12, Iss 1, p 42 (2012) |
| ISSN: | 1471-2415 |
| DOI: | 10.1186/1471-2415-12-42 |
| Popis: | Background To evaluate the treatment with topical 0.05% cyclosporine A (CsA) in patients with subepithelial corneal infiltrates (SEI). Methods We reviewed 16 patients (22 eyes) before and after the treatment with 0.05% CsA eye drops. All patients had been treated previously with topical corticosteroids without any improvement and also they had to stop the medication secondary to intraocular pressure elevation. The objective data recorded included best-corrected visual acuity (BCVA), evaluation of corneal subepithelial infiltrate scores (CSIS), intraocular pressure (IOP) prior to treatment and the last follow-up visit. Results Six males (37.5%) and 10 females (62.5%), mean age of 35.2 ± 16.6 years, were included. The patients’ average topical CsA use duration was 5.1 ± 3.5 months (1 – 13 months). The average follow up time of the patients was 9.2 ± 4.7 months (4 – 22 months). One patient, although he didn’t have a 0 scale of SCIS, did not show up for follow up examinations after six months. The mean BCVA (logarithm of the minimum angle of resolution) before and after the treatment were 0.15 ± 0.15 and 0.07 ± 0.07 respectively, CSIS 1.68 ± 0.89 and 0.23 ± 0.53 respectively, IOP 18.50 ± 3.82 and 16.86 ± 2.76 mmHg respectively. There were statistically significant improvements in BCVA (p = 0.002), reduction of CSIS (p = 0.002) and reduction of IOP (p Conclusions Topical 0.05% CsA is a safe and effective alternative treatment in patients with SEI who do not respond to other treatment modalities or have undesired side effects from topical steroids. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|